Abstract
Menkes disease is characterized by inhibition of the absorption and transport of dietary copper. The Okayama University Medical and Dental School uses L-histidine-copper to treat this disease and in the present study, we examined the stability of the copper histidinate injection solution used for this purpose. High-performance liquid chromatography (HPLC) performed on day 56 following injection revealed that histidine levels had dropped to 90.4%, a non-significant decrease and histamine levels were unchanged. Moreover, atomic absorption spectrophotometry revealed that copper concentrations were not significantly decreased (89.7%) between days 0 and 56. Through visual observation, we noted a gradual increase in floats from day 42 to day 56, leading us to suggest that the use of copper histidinate be limited to 1 month.The above results should alleviate any concern about histamine-associated adverse effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
